Skip to main content
TipRanks
Go Ultimate75% OFF

Serina Therapeutics (SER) Stock Price & Analysis

261 Followers

SER Stock Chart & Stats

$1.35-$0.01(-1.10%)
At close: 4:00 PM EST
$1.5$2$2.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.35 - $1.46
52-Week Range
$1.14 - $4.26
Previous Close
$1.37
Volume
N/A
Average Volume (3M)
61.95K
Market Cap
$35.87M
Enterprise Value
$34.79M
Total Cash (Recent Filing)
$19.40M
Total Debt (Recent Filing)
$3.37M
Price to Earnings (P/E)
―
Beta
0.86
Next Earnings
Mar 30, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Drug-delivery Platform

Serina’s POZ platform targets meaningful therapeutic improvements by extending drug action and potentially enhancing tolerability and efficacy. A reusable delivery technology can support multiple candidates and create strategic value beyond any single development program if clinical validation is achieved.

Low Leverage And Positive Equity

Very low debt reduces fixed financial obligations and preserves flexibility while the company funds research and development. Positive equity and a larger asset base than in prior annual reports provide a stronger capital foundation, although operating losses still require careful financing management.

Simplified Capital Structure

Eliminating the former preferred designation removes an outstanding security class and clarifies the current equity structure. This can simplify future corporate actions, make shareholder rights easier to understand, and provide greater flexibility when considering future financing instruments.

Bears Say

Minimal Commercial Revenue

The company has not yet demonstrated meaningful commercial revenue relative to its operating cost base. Large losses indicate that current activities remain dependent on development success, partnerships, or external capital rather than an established revenue engine with proven operating leverage.

Persistent Cash Burn

Deeply negative operating and free cash flow show that the business is consuming substantial cash to fund operations and development. Continued burn limits internal funding capacity and makes future progress dependent on securing additional capital before resources become constrained.

Equity Financing And Dilution Risk

The financing agreement improves access to working capital but relies on issuing new common shares, which can dilute existing holders as capital is raised. Dependence on equity funding also signals that ongoing operations and development may not yet be supported by internally generated cash.

Serina Therapeutics News

SER FAQ

What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.14 and its highest was $4.26 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $35.87M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 130 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Nov 12, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.338 by $0.028.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 26,569,458 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.338. Following the earnings report the stock price went down -1.418%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Hedge funds hold Serina Therapeutics shares: the largest hedge-fund position in Serina Therapeutics is 72,329,415 shares, and hedge funds decreased their holdings by 55.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology